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Background and Objectives. Disseminated intravascular
coagulation (DIC) is a syndrome characterized by sys-
temic intravascular activation of coagulation leading to
the widespread deposition of fibrin in the circulation.
Therefore, the determination of soluble fibrin is crucial for
the diagnosis of DIC. Thrombus precursor protein (TpP)
levels can be determined as a measure of soluble poly-
mers, which are the immediate precursors of insoluble
fibrin. In this study, the potential diagnostic usefulness
of this TpP test was investigated in septic patients with
DIC and liver diseases.
Design and Methods. TpP analysis was performed on
155 plasma samples from 95 septic patients, including
72 patients without liver disease and 23 patients with liv-
er diseases, and on 42 plasma samples from normal
healthy subjects. The study population was subdivided
according to three phases of DIC described as compen-
sated, decompensated and full-blown DIC. Plasma TpP
level was determined using a new assay, the TpPTM (Amer-
ican Biogenetic Sciences, USA), which is based on an
ELISA method.
Results. Septic patients with decompensated (16.1±9.1
µg/mL) or full- blown (20.9±12.4 µg/mL) phases of DIC
had significantly higher TpP levels than those with the
compensated (5.6±6.2 µg/mL) phase of DIC or healthy
controls (2.9±1.6 µg/mL). In septic patients with liver
disease, a significant difference was found between the
TpP levels of patients with full- blown DIC (21.6±10.6
µg/mL) and those of patients with the decompensated
phase (13.4±6.5 µg/mL). Plasma TpP levels correlated
significantly with other DIC parameters including platelet
count, fibrinogen, antithrombin and TAT, and correlated
weakly with D-dimer.
Interpretation and Conclusions. Our findings indicate
that septic patients who developed decompensated or
full-blown DIC or organ dysfunction have significantly
higher plasma levels of TpP, and suggest the potential
usefulness of the TpP assay as an aid to the diagnosis of
DIC in cases of sepsis and liver disease complicated by
sepsis.
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Disseminated intravascular coagulation (DIC)is a syndrome characterized by systemicintravascular activation of coagulation,
which leads to the widespread deposition of fibrin
in the circulation.1 One of the key events in the for-
mation of fibrin is the conversion of circulating
soluble plasma fibrinogen to insoluble cross-linked
fibrin polymer.2
Thrombin cleaves fibrinopeptide A from the fib-
rinogen molecule, exposing polymerization sites
on the newly formed desAA fibrin monomer units.
As the polymerization of desAA fibrin proceeds,
thrombin removes fibrinopeptide B from the fib-
rinogen molecule, which results in the formation
of a molecule known as desAABB fibrin.3 These sol-
uble polymers are the immediate precursors of
insoluble fibrin and are thus referred to as throm-
bus precursor protein (TpP). Elevated levels of this
protein are indicative of a prothrombotic state and
have been reported in clinical conditions in which
intravascular coagulation has been indicated.4-6
The most frequent disease states in which
intravascular coagulation occurs are infections
(systemic inflammatory response syndrome) and
liver diseases.7 According to the definition of DIC
stated above, the determination of soluble fibrin is
crucial for the diagnosis of DIC. In this study, the
potential diagnostic usefulness of TpP was inves-
tigated in septic patients with DIC and in patients
with liver diseases.
Design and Methods
TpP analysis was performed on 155 plasma sam-
ples from 95 septic patients, including 72 patients
without liver disease and 23 patients with liver
disease, and on 42 plasma samples from normal
healthy subjects. A clinical diagnosis of sepsis was
made based on the criteria of systemic inflamma-
tory response syndrome.8 Bacterial culture studies
in septic patients yielded the following informa-
tion: Gram positive cocci infections in 29 patients,
Gram negative bacilli infections in 29 patients, and
no growth in 14 patients. Of the 23 septic patients
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with liver disease, 2 had Gram positive cocci infec-
tions, 9 had Gram negative bacilli infections and no
growth was found in 12 patients.
The diagnosis of organ dysfunction was based on
criteria described elsewhere,9 but which can be
briefly summarized as follows: lung dysfunction,
PaO2 < 50 mmHg or the requirement of artificial
ventilatory support; kidney dysfunction, creatinine
level > 3 mg/dL or BUN > 50 mg/dL; heart dys-
function, systolic blood pressure of 90 mmHg or
less or heart failure; liver dysfunction, serum total
bilirubin > 5 mg/dL.
Patients were subdivided according to three
phases of DIC, namely, compensated activation of
the hemostatic system, decompensated activation
of the hemostatic system, and full-blown DIC,
defined by previously described criteria.10 In addi-
tion to prothrombin time (PT), activated partial
thromboplastin time (aPTT), platelet count, fib-
rinogen concentration, D-dimer, and antithrombin,
thrombin antithrombin complex (TAT) were deter-
mined to differentiate between the three phases of
DIC.
The blood samples were anticoagulated with 3.2%
sodium citrate and centrifuged at 2,000g for 10 min
immediately after venipuncture. Plasma was sepa-
rated and stored at –70°C until use. The plasma TpP
level was determined using an assay kit for TpPTM
(American Biogenetic Sciences, USA), which is based
on an ELISA method. In this assay, a murine mono-
clonal antibody, specific for soluble fibrin polymer,
is used as the capture antibody and another murine
monoclonal antibody, labeled with horseradish per-
oxidase is used to bind to a different site on the TpP
molecule. The monoclonal MH-1 antibody used is an
IgG1 (κ light chain) with a relatively high affinity for
cross-linked fibrin. The mean within-run coefficient
of variation of the TpP assay was 5.8% in samples
from 4 healthy subjects with normal TpP levels.
The plasma fibrinogen concentration was deter-
mined by Clauss’ method and the D-dimer con-
centration by latex agglutination immunoassay
(Diagnostica Stago, France). TAT, an indicator of
the amount of thrombin generated in the circula-
tion, was measured using an ELISA kit (Behringw-
erke, Germany).
The significance of the different values obtained
was analyzed using ANOVA and correlation coef-
ficients were calculated by linear regression analy-
sis using SAS software (SAS Institute Inc., North
Carolina, USA).
Results
The patients’ demographics and the results of the
laboratory tests of DIC parameters are summarized
in Tables 1 and 2.
Table 3 shows the mean TpP levels in 155 plas-
ma samples from 95 septic patients with dissemi-
nated intravascular coagulation and liver disease.
The 72 septic patients with decompensated phas-
es of DIC had significantly higher TpP levels
(16.1±9µg/mL and 20.9±12.4 µg/mL, respectively)
than those in the compensated phase of DIC or in
healthy controls (5.6±6.2 µg/mL and 2.9±1.6
Thrombus precursor protein in septic patients
Table 1. Demographic data of the study population.
Group Age (years) Sex Basal diseases Failured organ
Mean(SD) Male/Female
Sepsis 59 (19.6) 39/33 Pneumonia 16 Lung 28
without FUO 15 Kidney 21 
liver disease UTI 10 Heart 18
(n=72) Trauma 7 Liver 8 
Wound 6
Miscellaneous 18
Sepsis 52 (14.3) 14/9 LC 15
with liver HCC 4
disease AFH 4
(n=23)
FUO: fever of unknown origin; UTI: urinary tract infection; LC: liver cirrhosis;
HCC: hepatocellular carcinoma; AFH: acute fulminant hepatitis;
Miscellaneous: 3 acute cholangitis; 3 acute meningitis; 1 AIDS; 6 neoplasms;
3 stroke; 1 diabetes mellitus; 1 neurogenic bladder.
Table 2. Laboratory findings (mean ± SD) of coagulation in
72 septic patients with different phases of DIC.
Parameters Phase
Compensated (n=59) Decompensated (n=48) Full-blown(n=14)
Prothrombin time (sec) 15.4±5.3 18.5±9.0 20.8±5.9
APTT (sec) 46.2±21.5 55.7±25.1 60.3±20.8
Platelet count (/µL) 306,000±174,000 138,000±88.000 78,000±56,000
Fibrinogen (mg/dL) 496±166 356±198 166±97
D-dimer (µg/mL) 4.9±6.0 20.2± 53.3 28.4± 22.7
TAT (µg/L) 5.3±10.0 18.6±38.3 68.2±30.9
Antithrombin (%)* 79.4±22.1 69.1±29.6 50.6±20.9
APTT: activated partial thromboplastin time; TAT: thrombin-antithrombin complex.
*Data are missing for 9 patients.
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µg/mL, respectively). Within the septic patients
with liver disease, there was a significant difference
in the TpP levels between patients with full-blown
DIC (21.6±10.6 µg/mL) and those in a decompen-
sated phase of the DIC (13.4±6.5 µg/mL). Among
septic patients without liver disease, a significant
difference was found in the TpP levels of patients
with organ dysfunction (16.9±2.4 µg/mL) and the
patients without organ dysfunction (10.3±9.0
µg/mL) (Table 4).
The circulating TpP levels in 95 septic patients
including those with liver diseases correlated sig-
nificantly with other DIC parameters such as
platelet count (r=-0.2990, p=0.0002), fibrinogen
(r=-0.5041, p=<0.0001),  antithrombin (r=-0.2375,
p= 0.0327), and TAT (r = 0.3233, p = 0.0001) lev-
els, and correlated weakly with D-dimer (r=0.1649,
p = 0.0559) levels, as shown in Table 5 and Figures
1-5.
Discussion
It is agreed that DIC is an acquired disorder in
which the hemostatic system, involving platelets,
the coagulation system, fibrinolysis, and endothe-
lial cells, is activated, resulting in the conversion of
fibrinogen to fibrin.10 Quantification of activation
products of blood coagulation, such as soluble fib-
rin or fibrin monomer in plasma samples, are use-
ful for early identification of patients with in vivo
thrombin generation. However, soluble fibrin is not
a homogeneous molecular species as fibrin
monomers can form complexes with fibrinogen,
other fibrin monomers or with the degradation
products of fibrinogen or fibrin.11 Several methods
for measuring soluble fibrin or fibrin monomer in
plasma have been developed. These include com-
mercial assays based on the immunologic reactions
of antibodies against fibrin neo-epitopes exposed
by thrombin on fibrinogen.12-14 In addition, a mono-
clonal antibody has been developed that recog-
nizes an epitope region unique to the intact fibrin
Table 3. TpP levels (µg/mL) in 155 plasma samples from 95
septic patients with disseminated intravascular coagula-
tion (DIC) and liver disease.
Group n Mean SD Minimum Maximum p
Sepsis 121 <.0001*
Compensated 59 5.6 6.2 0.9 31.1
Decompensated 48 16.1 9.1 2.4 42.1
Full-blown 14 20.9 12.4 4.4 44.9
Sepsis with liver disease 34 0.0087°
Decompensated 19 13.4 6.5 3.8 29.3
Full-blown 15 21.6 10.6 8.8 70.0
Total 155 12.8 10.3 0.9 70.0 <.0001§
Normal controls 42 2.9 1.6 0.5 6.2
*p value between compensated, decompensated and full-blown DIC in septic
patients. °p value between decompensated and full-blown DIC in liver disease.
§p value between all septic patients and healthy normal controls.
TpP: thrombus precursor protein; SD: standard deviation.
Table 4. Comparison of TpP levels (µg/mL) between groups
with or without organ dysfunction in the septic patients with
disseminated intravascular coagulation.
Organ dysfunction n Mean SD Minimum Maximum p value*
No 61 10.3 9.0 0.9 31.1 0.0011
Yes 60 16.9 2.4 2.4 44.9
*p value between septic patients with and without organ dysfunction.
TpP: thrombus precursor protein; SD: standard deviation.
Table 5. Correlation of TpP with various hemostatic variables in septic patients with DIC and liver disease.
Correlation coefficients(r) TpP PT APTT Platelets Fibrinogen AT TAT D-dimer
(n=155) (n=155) (n=155) (n=148) (n=130) (n=81) (n=134) (n=135)
TpP 1.000 0.1221 0.0439 -0.2990* -0.5041* -0.2375° 0.3233* 0.1649§
PT 1.000 0.7374* -0.3304* -0.5288* -0.5643* 0.0235 0.1006
APTT 1.000 -0.2420° -0.4285* -0.4630* -0.0057 0.1291
Platelet 1.000 0.4739* 0.4687* -0.0957 -0.1609
Fibrinogen 1.000 0.6607* -0.2956° -0.2850°
Antithrombin 1.000 -0.0273 -0.1286
TAT 1.000 0 .3698*
D-dimer 1.000
*p value < 0.002, °p value < 0.05, §p value = 0.0559. TpP: thrombus precursor protein; DIC: disseminated intravascular coagulation; PT: prothrombin time;
APTT: activated partial thromboplastin time; AT: antithrombin; TAT: thrombin-antithrombin complex.
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polymer structure15 and it has been suggested that
the TpP assay could be useful as an aid to the diag-
nosis of myocardial infarction6 or acute chest pain
syndrome.16 However, the magnitude of TpP eleva-
tion in septic patients, in whom microthrombosis
is believed to play an important role in the devel-
opment of multiple organ failure, is unknown.
This study demonstrates that septic patients have
TpP concentrations from double to 20 times higher
than those of normal controls. When patients were
categorized according to which of three phases of
Thrombus precursor protein in septic patients
Figure 1. Correlation between TpP levels and platelet count
in septic patients.
Figure 2. Correlation between TpP levels and fibrinogen con-
centrations in septic patients.
Figure 3. Correlation between TpP levels and antithrombin
in septic patients.
Figure 4. Correlation between TpP levels and TAT in septic
patients.
Figure 5. Correlation between TpP levels and D-dimer in sep-
tic patients.
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DIC they had, TpP elevation was most obvious in the
septic patients in the full-blown phase of DIC, com-
pared with those with a stressed, but compensated
hemostatic system. In addition, plasma TpP levels
were significantly higher in cases of sepsis with
organ dysfunction than in cases of sepsis without
organ dysfunction.
In 1995, Dempfle et al.14 compared two immuno-
logic tests (Enzymum-Test FM and Fibrinostika sol-
uble fibrin) using monoclonal antibodies against
fibrin specific neo-epitopes to evaluate plasma
samples from healthy blood donors, patients with
cerebral ischemic insult, patients with septicemia
and patients with venous thrombosis. In the pre-
sent study, the upper limit in normal controls was
6.2 µg/mL, which is similar to that using the Enzy-
mum-Test FM (6.0 µg/mL), but different from that
using Fibrinostika soluble fibrin tests (2.1 µg/mL).
The discrepancy may be caused by different speci-
ficities of the monoclonal antibodies used and the
standard used to create the reference curves con-
tained in the individual assay kits.
In recent years, it has been shown that D-dimer
tests are more sensitive than assays of fibrino-
gen/fibrin degradation products (FDP) and that a
normal D-dimer level has a strong negative pre-
dictive value for the presence of intravascular fib-
rin degradation.17 In the present study, TpP values
correlated well with other DIC hemostatic markers,
which suggests that TpP measurement may have a
potential diagnostic role as a test for fibrin-relat-
ed materials in DIC. However, only a weak correla-
tion was found between TpP and D-dimer levels:
this may reflect the measurement of different sub-
populations of fibrin-related materials.
Because patients with chronic liver disease are
prone to develop DIC,18 and fibrin-related materials,
including FDPs, are metabolized by the liver,10 we
also determined the magnitudes of TpP elevation in
decompensated DIC and full-blown DIC in liver dis-
ease, and found that TpP was significantly higher in
the full-blown phase than in decompensated phas-
es. Our data suggest that TpP may be diagnostical-
ly useful in fulminant hepatic failure or in chronic
liver disease causing acute or chronic DIC.
Hypercoagulation may cause widespread micro-
embolism and is considered to be an important part
of the development of multiple organ failure; sol-
uble fibrin levels seem to predict organ system fail-
ure and outcome,19 consistent with our findings in
patients with or without organ dysfunction.
In conclusion, our findings indicate that septic
patients who develop decompensated or full-blown
DIC and organ dysfunction have significantly high-
er TpP plasma levels, and suggest the potential util-
ity of theTpP assay as an aid to the diagnosis of DIC
in sepsis and in liver disease.
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What is already known on this topic
Markers of thrombin generation may be helpful for the
diagnosis of disseminated intravascular coagulation in
septic patients.
What this study adds
Thrombin precursor protein is a novel marker that may
also be of value for this diagnosis.
Potential implications for clinical practice
Thrombin precursor protein may be useful for the diag-
nosis of DIC although prospective validation is required. 
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